PAT for the quarter ended December 31, 2024 was at Rs 348 crore

For the third quarter of FY 2025, Glenmark Pharma’s consolidated revenue was at Rs 3387.6 crore as against Rs 2506.7 crore recording an increase of 35.1 per cent YoY.

EBITDA was Rs 600 crore in the quarter ended December 31, 2024, with EBITDA margin of 17.7 per cent.

Profit After Tax (PAT) for the quarter ended December 31, 2024 was at Rs 348 crore, with a PAT margin of 10.3 per cent.

Glenn Saldanha, CMD, Glenmark Pharmaceuticals said, “We delivered strong and sustained growth this quarter, driven by robust performance across the regions. Our European business continued to perform well, while our branded markets demonstrated resilient growth. Strengthening our value-chain strategy, we secured MHRA authorisation for WINLEVI in the UK, marking a pivotal step in expanding our dermatology portfolio. Looking ahead, we expect our North America business to gain momentum from FY26 onwards, supported by our growing respiratory and injectable portfolio. Additionally, we reached a significant milestone with IGI presenting promising first clinical data from our Phase 1 study of the trispecific TREAT antibody, ISB 2001, at the 66th American Society of Hematology (ASH) Annual Meeting. We continue to explore strategic partnerships to advance this asset," he added.

Highlights for Q3 FY2025

· India Business grew by 300.2 per cent to Rs 1063.7 crore.

· Europe Business grew by 14.8 per cent to Rs 729.7 crore.

· RoW Business grew by 3 per cent to Rs 749.1 crore.

· North America Business grew by 1.4 per cent to Rs 781.3 crore.

· EBITDA of Rs 600 crore, with EBITDA margin of 17.7 per cent.

· Profit After Tax (PAT) of Rs 348 crore with PAT margin of 10.3 per cent.